close
Total Points: 1016
close
Edit Partner Bio
close
Add Position
close
Add Education
close
Profile
close
Profile
close
Partner Description
close
FOLLOWERS ()
close
Edit your post
close
EDIT APPLICATION
close
Start a Talk
Share articles, books, podcasts, ideas or questions that you think are important for other professionals to stay fresh and relevant.
close
Karel Petrak
New concepts in drug targeting at NangioTx
Comments
Keep the conversation going
Karel Petrak
New concepts in drug targeting at NangioTx
Joined 03/15/2016
Level: LEVEL 01 (12 mo pts: 0 pts)
Lifetime points: 1016 pts
Accomplishments:
- generated safety, toxicity and efficacy preclinical data, and designed several clinical studies (mucositis, necrotizing enterocolitis, head and neck cancer, severe sepsis) which showed talactoferrin to be effective in Phase 2 clinical studies. - raised $10+ MM federal funds to support the above clinical studies.
- led development of gene-based products for asthma, rheumatoid arthritis, and transplant rejection project funded by Syntex (later Roche) with a total budget of $17 million. I filed patents for the electroporation and ultrasonic-nebulization technologies for gene delivery.
- managed a testing laboratory and a data management/statistics group (staff of 20, monitoring 5000+ studies) and streamlined stability testing to achieve 20% reduction of the overall work-volume and costs.
- developed self-assembling nanoparticles that avoided recognition by the reticulo-endothelial system of the body – a property essential for a systemic delivery of site-specific systems.
- developed and patented new photographic and electro resist materials, a surfactant-specific electrode, and a method for measuring diffusion of oxygen through coated polymer layers. I also developed polymer/polymer interactions and phase separation systems which found a major practical application in the company’s coating technology.
Published over 100 scientific publications and patents.
Specialties: Project leadership and management in all aspects of drug research and development.
- generated safety, toxicity and efficacy preclinical data, and designed several clinical studies (mucositis, necrotizing enterocolitis, head and neck cancer, severe sepsis) which showed talactoferrin to be effective in Phase 2 clinical studies. - raised $10+ MM federal funds to support the above clinical studies.
- led development of gene-based products for asthma, rheumatoid arthritis, and transplant rejection project funded by Syntex (later Roche) with a total budget of $17 million. I filed patents for the electroporation and ultrasonic-nebulization technologies for gene delivery.
- managed a testing laboratory and a data management/statistics group (staff of 20, monitoring 5000+ studies) and streamlined stability testing to achieve 20% reduction of the overall work-volume and costs.
- developed self-assembling nanoparticles that avoided recognition by the reticulo-endothelial system of the body – a property essential for a systemic delivery of site-specific systems.
- developed and patented new photographic and electro resist materials, a surfactant-specific electrode, and a method for measuring diffusion of oxygen through coated polymer layers. I also developed polymer/polymer interactions and phase separation systems which found a major practical application in the company’s coating technology.
Published over 100 scientific publications and patents.
Specialties: Project leadership and management in all aspects of drug research and development.
close
Edit your Comment